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Abstract In the tilapia species Oreochromis niloticus, the
pituitary releases two forms of prolactins (tiPRL188 and
tiPRL177). The binding parameters and the activation of
tiPRL-induced JAK2/Stat5 signalling pathway were analysed
using a mammalian cell line transiently transfected with the
tiPRL receptor (tiPRLR). Our data indicate that the tiPRLR is
able to mediate transcriptional activation of the PRL responsive
element. At nanomolar concentrations, tiPRL188 activates gene
transcription whereas at micromolar concentrations it inhibits
luciferase transcription from the lactogenic responsive element.
This is consistent with a model of receptor dimerisation. In
contrast, the activation by tiPRL177 was only reached at high
(WM) concentrations. The transcriptional activities induced by
tiPRL177 and tiPRL188 are discussed in the context of the
physiology of these hormones.
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1. Introduction
Growth hormone (GH), prolactin (PRL) and somatolactin
belong to a family of vertebrate pituitary hormones. It has
been postulated that these hormones evolved from a common
ancestral gene through duplication and subsequent divergence
[1]. PRL is the most versatile of the pituitary hormones but its
primary action in ¢sh is its osmoregulatory role during fresh-
water adaptation [2].
Two forms of PRL have been identi¢ed in the tilapia spe-
cies Oreochromis niloticus and O. mossambiscus, one, a 177 aa
form (tiPRL177) and the other, a 188 aa form (tiPRL188)
which most closely resembles other ¢sh PRLs [3^5]. In both
species, the two tiPRLs clearly play a role in freshwater os-
moregulation. Studies aimed at identifying speci¢c actions of
each highly puri¢ed tiPRL in osmoregulation have not shown
di¡erences in hypophysectomised tilapia [3,6]. However, more
recent studies suggest that recombinant tiPRL188 possesses
greater sodium-retaining and calciotropic activity than does
recombinant tiPRL177 [7^9]. The actions of tiPRL177 may be
dependent on physiological status or may even be distinct, this
hormone possibly having acquired new functional activities
[10^12]. The recent cloning of a tilapia prolactin receptor
(tiPRLR) has furnished a new tool [13], allowing investiga-
tions on the intracellular dependent pathways induced by the
tiPRLs.
Activation of the mammalian PRL receptor (PRLR) occurs
following ligand-induced receptor dimerisation [14,15]. A
mathematical model has been developed for quantitative eval-
uation of biological responses associated with sequential di-
merisation [16]. PRL binding to PRLR activates intracellular
signalling factors such as Jak2, a non-receptor tyrosine kinase
that associates with the cytoplasmic domain of the PRLR [17^
19]. The signalling molecules recruited and activated by the
PRLR/Jak2 complex include the signal transducer and activa-
tor of transcription 5 (Stat5) [20].
In this report, we focus our attention on the e¡ects of the
two tiPRLs on the induction of the tiPRLR signal transduc-
tion. In the absence of a characterised tilapia cell line, we
transiently transfected the tiPRLR together with a lactogenic
hormone responsive element (LHRE) fused to a luciferase
reporter gene in the human HEK 293 cell line. We found
that the binding parameters and transcriptional activities de-
pendent on tiPRL177 and tiPRL188 parallel their biological
potencies on osmoregulation.
2. Materials and methods
2.1. Cultures and cells
Culture media and sera were purchased from Life Technologies,
Inc. The HEK 293 cell line was derived from human embryonic kid-
ney ¢broblasts transformed by human adenovirus type 5 (ATTC
CRL-1573).
2.2. Hormones
Recombinant tiPRL177 and tiPRL188 hormones were a gift from F.
Rentier-Delrue [5]. Recombinant tiGH was a gift from J. Smal
(Pharos, Sart Tilman, LieØge, Belgium). Labelled [125I]tiPRL177 and
[125I]tiPRL188 were obtained according to the chloramine T method
[7] and puri¢ed on Sephadex G75 columns by elution with phosphate
bu¡er (0.05 M, 0.1% BSA, pH 7.5). Fractions were aliquoted and kept
at 320‡C until used. The speci¢c activities of labelled hormones were
35^60 WCi/Wg (1.3^2.2 MBq/Wg).
2.3. Plasmids and construction of a mutant tiPRLR
cDNAs encoding the full length tiPRLR [13] and truncated mutant
tiPRLR263 were cloned into pcDNA3 vector (Invitrogen) under the
control of a cytomegalovirus promoter. The luciferase (Photinus pyr-
alis) reporter gene was cloned into pUC19 vector under the control of
thymidine kinase minimal promoter with or without (control: pUC19-
tk-Luc) a six times repeat of the LHRE, a Stat5 responsive element,
linked to the coding region of the luciferase reporter gene [21]. Trans-
fection was normalised with a L-galactosidase coding sequence under
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control of a CMV promoter (CMV-L-gal). The truncated mutant
tiPRLR263 was constructed by PCR using tiPRLR cloned into
pcDNA3 vector and the T7 primer (5P-ATACA-GACTCACTATAG-
GGAGAC-3P) of pcDNA3 as sense primers and an antisense primer
located after a proximal region of the transmembrane domain con-
served among cytokine receptors and called box1 (5P-CACCTCTCT-
AGAATCGCCACTCTTGAG-3P). A stop codon was inserted at po-
sition Lys264 with a restriction site for XbaI. The PCR product
contains the 5P-untranslated sequence, extracellular and transmem-
brane domains and stop codon downstream of the box1 coding region
of intracellular domain of the receptor. The tiPRLR263 thus retains
only 29 amino acids in its cytoplasmic domain instead of 372 in the
wild type tiPRLR [13]. The fragment was inserted into the XbaI and
HindIII sites of pcDNA3 vector and attested by sequencing [22].
2.4. Transient transfection in HEK 293 cells and dominant negative
e¡ects assays
Cells were cultured at 37‡C in 5% CO2 with DMEM/F12 medium
(Gibco) containing 10% calf foetal serum, 2 mM glutamine (Sigma)
and antibiotics (Sigma). Before transfection the cells were plated into
six well plates at 50% con£uence (500 000 cells per well) into 2 ml of
rich medium (culture medium supplemented with 1.5 g glucose/l).
Cells were transfected by the phosphate calcium method [23]. In
each well, cells were co-transfected with 10 ng of the receptor encod-
ing vector, 100 ng of the vector expressing the LHRE luciferase re-
porter gene and 500 ng of the L-galactosidase encoding vector. Within
24 h after transfection, cells were shifted to serum-free medium con-
taining the hormone to be tested. Hormones were assayed at concen-
trations ranging from 25 pM to 1.2 WM. After 16 h stimulation, cells
were lysed and luciferase and L-galactosidase activities measured (Lu-
mat LB 9501, Berthold, Nashua, NH). The relative light units were
normalised by L-galactosidase activity for each sample. The data are
presented as fold induction, de¢ned as the activity of stimulated sam-
ples (with hormone) versus activity of non-stimulated samples (with-
out hormone). For the dominant negative assay, increasing quantities
of vector expressing the mutant tiPRLR263 (0, 20 and 50 ng) were co-
transfected with the full length tiPRLR expression vector (10 ng), the
LHRE-luciferase reporter vector (100 ng) and the L-galactosidase
control vector (500 ng) and completed to a ¢nal concentration of
660 ng DNA with empty pcDNA3 vector [24]. After transfection
the cells were stimulated with 24 nM of tiPRL188.
2.5. Receptor binding assays
HEK 293 cells were transfected, in 100 mm dishes, with 4 Wg of full
length tiPRLR or truncated mutant/dish. After 48 h cells were scraped
in 2 ml cold 1UPBS and centrifuged for 30 min at 5000Ug. Cells were
resuspended in 0.5 ml of cold assay bu¡er (25 mM Tris-HCl, pH 7.5/
10 mM MgCl2) lysed by three freeze-thawed cycles and centrifuged 20
min at 15 000Ug. The pellet was resuspended in assay bu¡er and
protein concentration determined by the Bradford method [25]. Mem-
brane preparations (5^10 Wg) were incubated in assay bu¡er with 0.5%
BSA for 15 h at 20‡C, in the presence of 21 000 cpm of 125I-labelled
hormone and various concentrations of unlabelled hormones (¢nal
volume: 0.4 ml). Reactions were stopped by the addition of 2 ml
chilled assay bu¡er. Bound hormone was separated from unbound
hormone by centrifugation at 3000Ug for 30 min, and the superna-
tant removed. Pellets were counted in a LKB Q-spectrometer. Binding
parameters were determined using the LIGAND program [26].
2.6. Alignment of the PRLs
In order to compare di¡erences in functional domains involved in
binding a⁄nity between tiPRL177 and tiPRL188, amino acid sequence
alignments of these two hormones were performed using Clustal V
program of BISANCE [27]. The positions of helix and loop like the
¢rst and second sites associated with binding are shown in Fig. 5, as
determined from the sequence alignment of human PRL [28].
3. Results
3.1. Competition and Scatchard analysis
The tiPRLR was transiently expressed in HEK 293 cells
and used for binding experiments. The association constant
(Ka) of the expressed receptor for [125I]tiPRL188 was
2.4 þ 0.2U109 M31 (Fig. 1). The association constant of
[125I]tiPRL177 to tiPRLR transfected in HEK 293 cells was
6.0 þ 2U107 M31. The Kas of the two hormones are signi¢-
cantly di¡erent (n=3, P6 0.01, Student’s t-test). Next we per-
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Fig. 1. Homologous competition binding and Scatchard plot of 125I-
labelled tiPRL177 (b), tiPRL188 (a) and competition binding of
[125I]tiPRL188 by tiGH (F) to membrane from HEK 293 cells trans-
fected with tiPRLR cDNA. Membranes were incubated with various
concentrations of unlabelled hormones. Results are presented as per-
centage of maximal speci¢c binding observed without the competi-
tor. Each point represents the mean of three experiments. Represen-
tative Scatchard plots of each hormone, normalised per Wg protein,
are presented in the inset.
Fig. 2. Induction of the LHRE-luciferase reporter gene by tiPRLR
stimulated with tiPRL188 (a), tiPRL177 (b) or tiGH (F). The vector
expressing tiPRLR (10 ng) was co-transfected with vectors sharing
the inducible LHRE-tk-luciferase reporter gene (100 ng) and the
constitutive CMV-L-galactosidase reporter gene (500 ng). Cells were
stimulated and the fold induction of the LHRE-tk-luciferase pro-
moter calculated. Fold induction is de¢ned as the activity of the
promoter in presence of hormone on the activity without hormone.
Each point is the mean of three independent duplicates. Vertical
bars indicate the S.E.M.
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formed competition experiments of [125I]tiPRL188 by tiPRL177
and tiGH (Fig. 1). As expected, tiGH was unable to compete
with [125I]tiPRL188 in binding to the receptor. In agreement
with its binding a⁄nity, the tiPRL177 was seen to be a less
e⁄cient competitor for displacement than tiPRL188 and dis-
plays the same displacement curve when using [125I]tiPRL177
(data not shown).
3.2. tiPRL-induced transactivation of transcription
Both tiPRLs can activate transcription of the chimeric
LHRE reporter gene but each hormone induced a speci¢c
response. Interestingly, the tiPRL188 form activates transcrip-
tion at low concentrations (600 pM) with an EC50 of 15 nM
and maximal induction (V25U) between 25 and 50 nM. Up
to 120 nM, tiPRL188 showed a bell-shaped induction curve,
characteristic of self inhibition. The estimated self IC50 was
1.4^1.6 WM. The other form of prolactin, tiPRL177, is able to
activate LHRE transcription, but at concentrations much
higher than those for tiPRL188, with maximal induction
(27U) at 1.27 WM. The EC50 was 510 nM. Thus, the tiPRL188
which showed 35 times greater a⁄nity than tiPRL177 for the
receptor activated it at concentrations 33 times less. Due to
the limited quantity of tiPRL177 available, we were unable to
observe any bell-shaped curves with tiPRL177 at the concen-
trations tested (two di¡erent batches of puri¢ed hormone were
used with identical results). In agreement with the absence of
tiGH binding to the tiPRLR, this hormone was unable to
activate the transcription of luciferase gene up to a concen-
tration of 1.25 WM (Fig. 2). As expected, the minimal pro-
moter tk-luciferase did not induce any activation alone (data
not shown).
3.3. E¡ects of a cytoplasmic deletion in the tiPRLR
The mutant receptor, tiPRLR263, was constructed by di-
rected mutation resulting in loss of the majority of the cyto-
plasmic domain of tiPRLR but retaining the box1 region. The
a⁄nity of tiPRL188 for this truncated receptor tiPRLR263
was determined by Scatchard analysis of competition experi-
ments and found to be 2.6 þ 0.5U109 M31, similar to that of
the wild type receptor (n = 3, Fig. 3A). However, the truncated
tiPRLR263 was unable to transduce a signal (Fig. 3B). The
co-expression of the wild type tiPRLR and the truncated
tiPRLR263 inhibited transcription induced by the wild type
receptor in a dose-dependent manner (Fig. 4).
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Fig. 3. A: Competition binding and Scatchard plots of
[125I]tiPRL188 on wild type tiPRLR (b) and mutant tiPRLR263 (E)
expressed in HEK 293 cell line. Membranes were incubated in the
presence of ligand and various concentrations of unlabeled tiPRL188.
The results are expressed as percentage of the maximal speci¢c
binding observed in the absence of competitor. Wild type tiPRLR:
Ka = 2.4 þ 0.2U109 M31 ; tiPRLR263 Ka = 2.7 þ 0.5U109 M31
(n = 3). B: Induction of LHRE-tk-luciferase transcription in the
presence of wild type tiRPRL (b) or mutant tiPRLR263 (E). Ex-
perimental conditions as in Fig. 2. Each point is the mean of three
independent duplicates. Vertical bars indicate the S.E.M.
Fig. 4. Dominant negative e¡ect of tiPRLR263 on wild type
tiPRLR activity. The wild type tiPRLR (10 ng of vector) was co-
transfected with increasing quantities (0, 20 and 50 ng of vector) of
mutant or wild type receptor in HEK 293 cells (see Section 2). For
all studies, the overall quantity of expression vector was equalised
to 60 ng with empty pcDNA3 vector. The activity of tiPRLR is
measured as the capacity to induce transcription of LHRE-tk-luci-
ferase. The results are presented as percentage of activity in absence
of mutant receptor (10 ng of wild type tiPRLR+50 ng of pcDNA3).
The asterisk indicates signi¢cant inhibition of transcription com-
pared to both control without mutant receptor and tiPRLR trans-
fected under the same conditions (n = 3, P6 0.005, Duncan’s multi-
ple range test) performed in triplicate. The mutant tiPRLR263
expressed without wild type receptor is unable to induce transcrip-
tion at all concentrations of vectors (10, 30 and 60 ng) (data not
shown).
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4. Discussion
Both tiPRLs are able to bind the tiPRLR expressed in
HEK 293 cells and induce a dose-dependent transcriptional
activities of the LHRE-tk-luciferase construct. The tiPRLR
shares the same overall structure as the long form of the
mammalian PRLR [13]. However, amino acid conservation
in the cytoplasmic domain, implicated in the signal transduc-
tion, is low, corresponding to only 26^30% sequence iden-
tity [13]. Nevertheless the strong conservation of restricted
regions along this domain, like the proline-rich region
(box1 = PPVPGP), appears su⁄cient to ensure a signi¢cant
activation of the LHRE-tk-luciferase reporter gene, a Stat5
responsive gene in mammalian cell lines. Moreover, although
no di¡erence in binding a⁄nity was observed between the
wild type receptor and the tiPRLR263, the latter was unable
to activate the Stat5-dependent transcription when expressed
alone. Furthermore, co-transfection of the tiPRLR263 inhib-
ited the activation induced by the wild type tiPRLR in a dose-
dependent manner, possibly indicating an e¡ect due to in-
creasing quantities of inactive wild type/mutated hetero-
dimers. Thus, although no short form PRLR has so far
been observed in tilapia, the tiPRLR263 mutant appears to
behave like the mammalian short form receptor [24]. Taken
together, these results indicate a strong conservation of the
structure functionality required for the PRLR signalling path-
ways from ¢shes to mammals, as limited common features are
required for Jak/Stat pathway activation.
Another feature associated with PRL or GH e¡ects in
mammals resides in the bell-shaped dose-response curves dis-
played during promoter activation [16,29,30]. Brie£y, the ac-
tivation of the receptor is a two-step process directed by the
hormone. During the ¢rst step, the hormone recruits, via a
¢rst interaction site, one receptor molecule. This complex (1:1
hormone/receptor) is unable to transduce the signal. In a sec-
ond step, the complex binds another receptor molecule to
form the active receptor homodimer complex (1:2 hormone/
receptors). The ¢rst and second hormone binding sites are
di¡erent. Because the second site remains masked until the
¢rst site has bound a receptor molecule, the process of dimer-
isation is sequential. As a consequence, if the a⁄nity of the
¢rst binding site for the receptor is greater than that of the
second site, formation of inactive (1:1) hormone/receptor
complexes are favoured at high hormone concentrations,
and self antagonism occurs displaying a bell-shaped activation
curve. The pro¢le of luciferase expression using tiPRL188 in
our studies agrees with such homodimerisation model. These
data clearly indicate that the tiPRL188-induced homodimerisa-
tion of tiPRLR is the preliminary and necessary event for its
biological e¡ect.
Unfortunately, the quantities of tiPRL177 available were not
su⁄cient to obtain a bell-shaped curve with this hormone.
This does not mean that the dimerisation is not necessary to
the activation of the receptor by the tiPRL177. In fact, the
perfect proportionality observed comparing the binding (Ka)
and activation (EC50) data for both hormones argues rather
for a similar mechanism. If a dimerisation-dependent activa-
tion of the receptor by the tiPRL177 is postulated, the
tiPRL177 peak shifting towards high concentrations might in-
dicate that the tiPRL177 displays a lower ability to bind the
¢rst receptor molecule than does the tiPRL188. Similarly, the
maximal induction achieved by tiPRL177, equivalent to that
obtained with tiPRL188, might indicate that the second site of
both hormones is equipotent. The comparison of the sequen-
ces of the tiPRLs shows that all the essential charged amino
acid residues (hydrophobic or hydrophilic) in the ¢rst site
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Fig. 5. Alignment of the two prolactins of tilapia (O. niloticus) and ovine prolactin. H1, H2, H3 and H4 are the four K helices; L1, L2 and L3
the three interhelical loops. The positions of loops and helices, like the emplacement of residues forming the ¢rst and second binding sites (re-
spectively site 1 and 2), are reported according to sequence alignment with human prolactin (not shown). Asterisks indicate amino acids fully
conserved between the three PRLs, the dots similar amino acids, and hyphens the deleted amino acids.
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forming region (helix 1/helix 4/loop 1) are either unmodi¢ed
or substituted by homologous residues in both tilapia PRLs,
the main di¡erence being the ¢ve residues deleted in both loop
1 and helix 4 of the tiPRL177 (Fig. 5). These deletions might
create a steric hindrance in the ¢rst binding site, reducing its
potency to bind the ¢rst molecule of receptor and then the
ability of the tiPRL177 to activate the receptor. Similar results
have been recently obtained using 22 kDa hGH and its 20
kDa isoform on hGH receptor [31].
These data are in good agreement with the observations
performed in short-term acclimatised tilapia after transfer to
brackish water. Only one single class of tiPRL receptor was
detected, with tiPRL188 being the most potent ligand com-
pared to tiPRL177 [7,32,33]. Furthermore, the biological e¡ec-
tiveness of tiPRL188 was also signi¢cantly higher on plasma
osmolality, thus corroborating binding parameters [7^9,34]. In
O. niloticus species, a converse situation implicating these two
tiPRL hormones has been described recently [10,11]. The ef-
fects of the tiPRLs on pigment dispersion in cultured xantho-
phores and erythrophores showed inverted potencies. These
comprised dose-related e¡ects in nM range for tiPRL177 ver-
sus e¡ectiveness for tiPRL188 only at WM concentrations. The
mechanisms underlying the reverse responsiveness to each of
the two tiPRLs in these two models in vivo are yet unknown
and may implicate as well hormone/cell type-speci¢c signalling
pathways as the existence of di¡erent receptors displaying
inverted a⁄nities for the tiPRL188 and the tiPRL177.
In our study based on the tiPRL/tiPRLR-induced Jak2/
Stat5 transduction pathway, the biological e¡ectiveness of
tiPRL188 and tiPRL177 requires respectively low (nM) and
high hormone concentrations close to WM. Thus, the parallel
responsiveness of the two tiPRLs in our model and osmore-
gulatory organs strongly suggests that their e¡ect on water,
sodium and chloride movements in ¢sh might be dependent
on the Stat5 signalling pathway.
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